A type 2 diabetes drug discovered by Vitae Pharmaceuticals Inc. and partnered with Boehringer Ingelheim GmbH failed to meet Boehringer's primary efficacy endpoint – change in fasting plasma glucose – when combined with the common diabetes medicine metformin in an ongoing phase II study.